These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1123 related articles for article (PubMed ID: 1293168)

  • 1. Serum 5-S-cysteinyldopa (5-S-CD) as a marker of melanoma progression.
    Horikoshi T; Ito S
    J Dermatol; 1992 Nov; 19(11):809-13. PubMed ID: 1293168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of melanin-related metabolites as markers of melanoma progression.
    Horikoshi T; Ito S; Wakamatsu K; Onodera H; Eguchi H
    Cancer; 1994 Feb; 73(3):629-36. PubMed ID: 8299084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normal values of urinary excretion and serum concentration of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid, biochemical markers of melanoma progression.
    Wakamatsu K; Ito S; Horikoshi T
    Melanoma Res; 1991; 1(2):141-7. PubMed ID: 1823626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-S-cysteinyldopa in urine and tumors.
    Hara H; Chino K; Kawanami T; Sameshima T; Morishima T
    J Dermatol; 1992 Nov; 19(11):806-8. PubMed ID: 1293167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Production, circulation, and excretion of melanin-related metabolites in B16 melanoma-bearing mice.
    Wakamatsu K; Ito S; Fujita K
    Acta Derm Venereol; 1990; 70(5):367-72. PubMed ID: 1980967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma.
    Kärnell R; von Schoultz E; Hansson LO; Nilsson B; Arstrand K; Kågedal B
    Melanoma Res; 1997 Oct; 7(5):393-9. PubMed ID: 9429222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression: 10 years' experience.
    Wakamatsu K; Kageshita T; Furue M; Hatta N; Kiyohara Y; Nakayama J; Ono T; Saida T; Takata M; Tsuchida T; Uhara H; Yamamoto A; Yamazaki N; Naito A; Ito S
    Melanoma Res; 2002 Jun; 12(3):245-53. PubMed ID: 12140381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biochemical diagnoses of malignant melanomas with determinations of 5-S-cysteinyldopa in lesions].
    Sameshima T; Morishima T
    Nihon Hifuka Gakkai Zasshi; 1989 May; 99(6):665-72. PubMed ID: 2511358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum concentration of 5-S-cysteinyldopa in patients with melanoma.
    Bánfalvi T; Gilde K; Boldizsár M; Fejös Z; Horváth B; Liszkay G; Beczássy E; Kremmer T
    Eur J Clin Invest; 2000 Oct; 30(10):900-4. PubMed ID: 11029605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum 5-S-cysteinyldopa behavior in the early phase of nivolumab treatment of 12 melanoma patients.
    Omodaka T; Minagawa A; Uhara H; Wakamatsu K; Koizumi T; Yokokawa Y; Koga H; Okuyama R
    J Dermatol; 2018 Nov; 45(11):1340-1344. PubMed ID: 30144152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of cysteinyldopa in the follow-up of disseminated malignant melanoma.
    Kärnell R; Kågedal B; Lindholm C; Nilsson B; Arstrand K; Ringborg U
    Melanoma Res; 2000 Aug; 10(4):363-9. PubMed ID: 10985671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy.
    Wimmer I; Meyer JC; Seifert B; Dummer R; Flace A; Burg G
    Cancer Res; 1997 Nov; 57(22):5073-6. PubMed ID: 9371505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seasonal variation in serum concentration of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid in healthy Japanese.
    Wakamatsu K; Ito S
    Pigment Cell Res; 1995 Jun; 8(3):132-4. PubMed ID: 7567788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of malignant melanoma: disease progression correlated with serum levels of 5-S-Cysteinyldopa (5-S-CD) and intercellular adhesion molecule-1 (ICAM-1).
    Ye Z; Kageshita T; Ishihara T; Ito S; Ono T
    J Dermatol; 1995 May; 22(5):370-5. PubMed ID: 7673560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of phaeomelanin and its precursor 5-S-cysteinyldopa in the serum of melanoma patients.
    Wakamatsu K; Yokochi M; Naito A; Kageshita T; Ito S
    Melanoma Res; 2003 Aug; 13(4):357-63. PubMed ID: 12883361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of serum 5-S-CD and S-100B protein levels to monitor the clinical course of malignant melanoma.
    Bánfalvi T; Gilde K; Gergye M; Boldizsár M; Kremmer T; Ottó S
    Eur J Cancer; 2003 Jan; 39(2):164-9. PubMed ID: 12509947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of 5-S-cysteinyldopa monitoring in patients with malignant melanoma.
    Bánfalvi T; Gilde K; Boldizsár M; Kremmer T
    Neoplasma; 2002; 49(2):121-5. PubMed ID: 12088105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [5-S-cysteinyldopa as a tumor marker for primary uveal malignant melanoma].
    Goto H; Tenou T; Kudo H; Iwasaki T; Muramatsu R; Usui M; Wakamatsu K; Ito S
    Nippon Ganka Gakkai Zasshi; 1998 May; 102(5):319-26. PubMed ID: 9619024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the clinical usefulness of measuring urinary excretion of 5-S-cysteinyldopa in melanoma: ten years' experience of 50 patients.
    Sasaki Y; Shimizu H; Naka W; Takeshita E; Nishikawa T
    Acta Derm Venereol; 1997 Sep; 77(5):379-81. PubMed ID: 9298132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression.
    Bánfalvi T; Gilde K; Boldizsár M; Kremmer T; Ottó S
    Pathol Oncol Res; 1999; 5(3):218-22. PubMed ID: 10491021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.